Ruo‐Jing Li

2.3k total citations
33 papers, 1.8k citations indexed

About

Ruo‐Jing Li is a scholar working on Molecular Biology, Oncology and Biomaterials. According to data from OpenAlex, Ruo‐Jing Li has authored 33 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Biomaterials. Recurrent topics in Ruo‐Jing Li's work include RNA Interference and Gene Delivery (8 papers), Nanoparticle-Based Drug Delivery (5 papers) and Lysosomal Storage Disorders Research (3 papers). Ruo‐Jing Li is often cited by papers focused on RNA Interference and Gene Delivery (8 papers), Nanoparticle-Based Drug Delivery (5 papers) and Lysosomal Storage Disorders Research (3 papers). Ruo‐Jing Li collaborates with scholars based in China, United States and Macao. Ruo‐Jing Li's co-authors include Wan-Liang Lü, Hong-Juan Yao, Rui-Jun Ju, Xue Ying, Ying Men, Yang Yu, Xiaoxing Wang, Ju Du, Wei Tian and Jinning Lou and has published in prestigious journals such as Neuron, Blood and Biomaterials.

In The Last Decade

Ruo‐Jing Li

33 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruo‐Jing Li China 19 936 716 410 329 134 33 1.8k
Annette Burkhart Denmark 13 499 0.5× 322 0.4× 228 0.6× 199 0.6× 74 0.6× 22 1.3k
Anthony Régina Canada 24 1.4k 1.5× 720 1.0× 339 0.8× 1.1k 3.5× 159 1.2× 39 3.1k
Xiyang Sun China 20 831 0.9× 582 0.8× 653 1.6× 147 0.4× 242 1.8× 32 2.0k
Gloria Perazzoli Spain 23 752 0.8× 364 0.5× 314 0.8× 263 0.8× 61 0.5× 67 1.6k
Xiao Gu China 20 712 0.8× 355 0.5× 380 0.9× 176 0.5× 105 0.8× 40 1.6k
Suresh Kumar Swaminathan United States 15 935 1.0× 259 0.4× 223 0.5× 315 1.0× 76 0.6× 24 1.6k
Shengpeng Wang China 24 1.2k 1.3× 332 0.5× 232 0.6× 137 0.4× 75 0.6× 57 2.7k
Claudia Koch-Brandt Germany 16 631 0.7× 352 0.5× 161 0.4× 524 1.6× 166 1.2× 25 1.4k
Zhonglian Cao China 26 934 1.0× 373 0.5× 549 1.3× 212 0.6× 43 0.3× 53 2.1k
Jung Jin Hwang South Korea 27 1.4k 1.5× 256 0.4× 179 0.4× 259 0.8× 58 0.4× 75 2.7k

Countries citing papers authored by Ruo‐Jing Li

Since Specialization
Citations

This map shows the geographic impact of Ruo‐Jing Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruo‐Jing Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruo‐Jing Li more than expected).

Fields of papers citing papers by Ruo‐Jing Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruo‐Jing Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruo‐Jing Li. The network helps show where Ruo‐Jing Li may publish in the future.

Co-authorship network of co-authors of Ruo‐Jing Li

This figure shows the co-authorship network connecting the top 25 collaborators of Ruo‐Jing Li. A scholar is included among the top collaborators of Ruo‐Jing Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruo‐Jing Li. Ruo‐Jing Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Ruo‐Jing, et al.. (2025). Evaluation of the Landscape of Pharmacodynamic Biomarkers in GM1 and GM2 Gangliosidosis. Clinical and Translational Science. 18(3). e70176–e70176. 1 indexed citations
2.
Li, Ruo‐Jing, et al.. (2024). Clinical pharmacology considerations for first‐in‐human clinical trials for enzyme replacement therapy. Journal of Inherited Metabolic Disease. 47(5). 1096–1106. 1 indexed citations
3.
Zhang, Kai, et al.. (2024). Occurrence characteristics and influencing factors of antibiotic resistance genes in rural groundwater in Henan Province. Environmental Science and Pollution Research. 31(11). 16685–16695. 1 indexed citations
4.
5.
Woods, Ashley, Kelly J. Norsworthy, Jonathon Vallejo, et al.. (2023). FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. Clinical Cancer Research. 30(7). 1226–1231. 16 indexed citations
6.
Li, Ruo‐Jing, Lian Ma, Katarzyna Drozda, et al.. (2023). Model-Informed Approach Supporting Approval of Nexviazyme (Avalglucosidase Alfa-ngpt) in Pediatric Patients with Late-Onset Pompe Disease. The AAPS Journal. 25(1). 16–16. 6 indexed citations
7.
He, Fang, Mahendra Damarla, Rongju Sun, et al.. (2023). Dimethyl Fumarate Protects against Lipopolysaccharide- (LPS-) Induced Sepsis through Inhibition of NF-κB Pathway in Mice. Mediators of Inflammation. 2023. 1–10. 9 indexed citations
8.
Xin, Rui, Yongzhen Ding, Keqiang Zhang, et al.. (2023). Tracking the extracellular and intracellular antibiotic resistance genes across whole year in wastewater of intensive dairy farm. Ecotoxicology and Environmental Safety. 269. 115773–115773. 7 indexed citations
9.
Suzuki, Mari, Linda Jo Bone Jeng, Yan Wang, et al.. (2022). FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. Genetics in Medicine. 25(2). 100335–100335. 20 indexed citations
10.
Li, Ruo‐Jing, Lian Ma, Hyewon Kim, et al.. (2022). Model-Informed Approach Supporting Approval of Adalimumab (HUMIRA) in Pediatric Patients with Ulcerative Colitis from a Regulatory Perspective. The AAPS Journal. 24(4). 79–79. 5 indexed citations
11.
Kasamon, Yvette L., Lauren Price, Ólanrewaju O. Okusanya, et al.. (2021). FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The Oncologist. 26(10). 879–886. 25 indexed citations
12.
Mehta, Sohum, et al.. (2015). Visualization of Compartmentalized Kinase Activity Dynamics Using Adaptable BimKARs. Chemistry & Biology. 22(11). 1470–1479. 23 indexed citations
13.
Lü, Wan-Liang, Ruo‐Jing Li, Yan Zhang, et al.. (2011). The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals. International Journal of Nanomedicine. 6. 3125–3125. 22 indexed citations
14.
Yu, Yang, Zhaohui Wang, Liang Zhang, et al.. (2011). Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials. 33(6). 1808–1820. 87 indexed citations
15.
Zhang, Liang, Hong-Juan Yao, Yang Yu, et al.. (2011). Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials. 33(2). 565–582. 109 indexed citations
16.
17.
Yao, Hong-Juan, Rui-Jun Ju, Xiaoxing Wang, et al.. (2011). The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials. 32(12). 3285–3302. 140 indexed citations
18.
Li, Ruo‐Jing, Xue Ying, Yan Zhang, et al.. (2010). All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. Journal of Controlled Release. 149(3). 281–291. 102 indexed citations
19.
Tian, Wei, Xue Ying, Ju Du, et al.. (2010). Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats. European Journal of Pharmaceutical Sciences. 41(2). 232–243. 52 indexed citations
20.
Ying, Xue, He Wen, Wan-Liang Lü, et al.. (2009). Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. Journal of Controlled Release. 141(2). 183–192. 358 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annette Burkhart Breakdown of academic impact, for papers by Anthony Régina Breakdown of academic impact, for papers by Xiyang Sun Breakdown of academic impact, for papers by Gloria Perazzoli Breakdown of academic impact, for papers by Xiao Gu Breakdown of academic impact, for papers by Suresh Kumar Swaminathan Breakdown of academic impact, for papers by Shengpeng Wang Breakdown of academic impact, for papers by Claudia Koch-Brandt Breakdown of academic impact, for papers by Zhonglian Cao Breakdown of academic impact, for papers by Jung Jin Hwang
Rankless by CCL
2026